News

Dirty equipment and sterilization issues are among the many violations found by the FDA.

Technology offers accessibility, scalability to countries where care is needed the most.

Cochair Elizabeth Yeu, MD, highlights what this program will mean for ophthalmologists, optometrists, and their patients.

Lisa M. Nijm, MD, MD, highlights what residents, fellows, and ophthalmologists who are early in their careers can expect at the virtual Real World Ophthalmology meeting on Saturday, April 15.

The company could also consider partnerships or licensing agreements for some drugs of its ophthalmology pipeline, including pegcetacoplan.

Despite the injection of intravitreal antibiotics at the end of corrective surgery, delayed-onset endophthalmitis can develop in patients who sustained open globe injuries.

Evolving technology is resulting in better outcomes for patients.

The first 2023 release of the Video Journal of Cataract, Refractive, & Glaucoma Surgery explores essential techniques for intraocular lens (IOL) removal, providing a diverse range of both routine and novel approaches within its hour-long presentation.

According to National Eye Institute researchers, the strategy may speed the delivery of therapeutic options relative to time it would take to develop gene therapies.

The month will serve to educate the public on a variety of women’s vision issues.

Brimonidine Tartrate Ophthalmic Solution is an alpha-adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma.

According to the company, clinically meaningful visual acuity gains were observed in several MCO-010 treated patients. The trial also demonstrated a favorable safety profile for MCO-010 with no serious or severe adverse events.

Disruption affected ophthalmology, altering physicians’ education, careers.

Researchers at Buck Institute, working with Google Health and Zuckerberg San Francisco General Hospital, are studying the eye as a window into human aging.

Allergan developed VUITY, which it noted is the first and only FDA-approved eye drop to treat presbyopia. The FDA has now approved a two-dose option.

The Centers for Medicare and Medicaid Services accepted comments on the proposed rule and several organizations, including the American Academy of Ophthalmology, chimed in with comments and offered suggestions.

Lotilaner ophthalmic solution, 0.25% is the first drug designed to treat and target the underlying cause of Demodex blepharitis, according to investigators.

Many patients with diabetes can be stabilized with anti-VEGF biologics.

Ehsan Sadri, MD, FACS, and William Trattler, MD, highlight some of the pending FDA approvals and PDUFA dates in the anterior segment sector and what these products will mean for ophthalmologists and their patients.

GAL-101 is a Phase 2/3-ready small molecule used to treat ophthalmic indications with high unmet medical need.

According to researchers at UCLA, “dormant” cone photoreceptors might continue to drive retinal activity for vision.

Ophthalmologist looks ahead amid company’s advances over past 18 months.

The company’s market tracker enables comprehensive brand-level market analysis and direct access to real-world data from the IRIS Registry.

Nitish Mehta, MD discusses the latest trends in Artificial Intelligence and Machine Learning technology in retinal imaging and its uses for ophthalmologists.

The study of UBX1325 is in patients with wet age-related macular degeneration (AMD) who were not achieving optimum benefit with their ongoing anti-VEGF therapy.

The Phase 1/2 Clinical Trial is for the treatment of retinitis pigmentosa and Leber congenital amaurosis.

Ophthalmologists have discussions about driving with glaucoma patients.

It is important for patients to understand what digital eye strain is and its causes.